EyeGene Inc.   Report issue

For profit Phase 1
Founded: Seoul Korea, Republic of (2006)

Organization Overview

First Clinical Trial
2020
NCT04210752
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

EyeGene Inc.